Aims There are few studies of the use of intra-aortic balloon pump (IABP) treatment as a bridge to heart transplantation (HTx). This is the first study to compare long-term clinical and haemodynamic ...
Despite a lack of evidence, circulatory support with intraaortic balloon counterpulation (IABP) has a class 1 recommendation in the guidelines and is often used in patients in cardiogenic shock ...
Intra-aortic balloon pump counterpulsation prior to PCI in patients with ST segment elevation MI does not reduce infarct size as measured by MRI, according to results from the Counterpulsation Reduces ...
Please provide your email address to receive an email when new articles are posted on . Infarct size as measured by MRI does not reduce when intra-aortic balloon pump counterpulsation is used before ...
Paris, France, 30 August: Intra-aortic balloon pump counterpulsation prior to PCI in patients with ST segment elevation MI does not reduce infarct size as measured by MRI, according to results from ...
MUNICH and WAYNE, N.J., Aug. 27, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, the market leader in intra-aortic balloon counterpulsation therapy, today announced 30-day results from the large, ...
CHICAGO, IL—Contrary to shorter-term results, follow-up beyond 4 years shows that elective intra-aortic balloon pump (IABP) therapy in high-risk patients receiving percutaneous coronary intervention ...
The results of the Intraaortic Balloon Pump in Cardiogenic Shock (IABP-SHOCK) II trial, presented at the 2012 European Society of Cardiology Congress and published in the New England Journal of ...
MUNICH, Germany—Although use of an intra-aortic balloon pump (IABP) in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock appears safe, the technique does not improve ...
Please provide your email address to receive an email when new articles are posted on . A routine strategy of intra-aortic balloon counterpulsation before percutaneous coronary intervention did not ...
ANGIODROID Srl, an Italian manufacturer of medical technologies, announces the CE mark for ANGIOPULSE, its first intra-aortic balloon pump (IABP) device. (Photo ...
This study demonstrates that IABP is a valuable tool as a bridge to HTx in patients with end-stage heart failure. Kaplan–Meier analysis revealed no significant difference in post-HTx survival between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results